Co-Epril

Quick links to important sections

Co-Epril

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Co-Epril

Property Description
Active ingredients Enalapril maleate, Hydrochlorothiazide
Form Oral tablet
Pharmacological class Antihypertensive Agent (ACE Inhibitor and Thiazide Diuretic)
General purpose Management of high blood pressure (Hypertension)
Origin Synthetic

Defining Co-Epril: A Fixed-Dose Combination Antihypertensive

Co-Epril is classified as a Fixed-Dose Combination (FDC) Antihypertensive Agent, a prescription-only medication intended for the sustained management of elevated blood pressure in adults. This synthetic drug is delivered as an oral tablet, distinguishing it from liquid or injectable forms. The FDC structure is a clinically recognized approach for blood pressure management protocols. This approach provides two independent ways to address blood pressure simultaneously, which can be more effective than using a single agent.

What Active Ingredients Make Up Co-Epril?

The medication is composed of two primary active ingredients: Enalapril maleate and Hydrochlorothiazide. Enalapril maleate is an Angiotensin-Converting Enzyme (ACE) Inhibitor, while Hydrochlorothiazide belongs to the Thiazide Diuretic class. Similar FDC formulations exist under other names, such as Vaseretic. Combining these two different types of synthetic agents allows the medication to influence both the vascular tone and the body's fluid volume.

General Purpose: Why is a Dual-Action Formula Used?

The general purpose of Co-Epril's dual formula is to achieve a synergistic effect, offering a more efficient and comprehensive reduction of high blood pressure. This action combines the vessel relaxation promoted by the ACE Inhibitor with the volume reduction resulting from the Thiazide Diuretic. The clinical utility of this strategic pairing is used for controlling hypertension and supporting the long-term health of the cardiovascular system.

What side effects are possible with Co-Epril?

Possible Side Effects and Safety Information

Co-Epril, which contains an ACE inhibitor and a diuretic, has a documented safety profile derived from regulatory sources. Its use is associated with a range of possible side effects, categorized by frequency and severity.

Frequency Common Adverse Reactions (Approx. 1 in 100 to 1 in 10)
Common Headache, dizziness, fatigue, cough, and hypotension (low blood pressure).

Serious and clinically significant adverse reactions are rare but require immediate attention and drug cessation. These include angioedema, which is rapid swelling of the face, lips, tongue, or throat and may be life-threatening. Other serious risks involve the renal system (e.g., acute renal failure, especially in susceptible patients) and hematologic system (e.g., agranulocytosis or neutropenia).

Safety Considerations and Restrictions

The most significant safety restriction is a Boxed Warning regarding use during pregnancy. Co-Epril is contraindicated in the second and third trimesters as it may cause injury and death to the developing fetus; it should be discontinued immediately if pregnancy is detected. Use is also contraindicated in patients with a history of angioedema related to previous ACE inhibitor use, and generally with aliskiren in diabetic patients. The drug requires cautious use in patients with pre-existing renal impairment, where regular monitoring of serum creatinine and potassium levels is recommended. Due to the diuretic component, the risk of electrolyte imbalances (such as hypo- or hyperkalemia) and dehydration also requires clinical monitoring.

Overdose and Emergency Response

Overdose Manifestations and Emergency Action

The official regulatory profile for Co-Epril overdose describes clinical manifestations stemming from the actions of both Enalapril and Hydrochlorothiazide. The primary documented risk is profound systemic hypotension (dangerously low blood pressure), which may rapidly lead to circulatory shock or collapse. Overdose also presents with severe disturbances in fluid and electrolyte balance, notably hypokalemia (low potassium) and hyponatremia, which can potentially trigger cardiac arrhythmias. Documented signs may also include dizziness, stupor, and vomiting.

All suspected or confirmed cases of overdose require immediate medical attention. Regulators mandate contacting emergency services or a Poison Control Center immediately and require close hospital observation to monitor vital signs and laboratory parameters, such as serum electrolytes and renal function. Severe consequences include the risk of acute renal failure, a risk noted particularly for patients with pre-existing impaired renal function.

Management and Antidote Status

In terms of management, regulatory documents state that no specific antidote is known for Co-Epril. Treatment is universally symptomatic and supportive, focusing on the intravenous infusion of saline solution to rapidly correct hypotension and volume depletion. The ACE inhibitor component, Enalapril, is documented as being removable by hemodialysis.

Therapeutic Uses of Co-Epril

What Co-Epril Treats: Main Uses and Benefits

Co-Epril is generally used in situations involving certain distressing symptoms. It is considered relevant in contexts marked by increased discomfort or tension where additional symptomatic support is needed.

This combination is used in the management of two main conditions: high blood pressure and may also be used for heart failure. By contributing to the management of these chronic conditions, it provides support that helps ease the overall symptom load and assists with maintaining functional stability during symptomatic periods.

Symptom and Condition Management

This medication is commonly used across conditions presenting with acute episodes characterized by periods of heightened symptoms. It is also applied when symptoms related to conditions like heart failure, such as fluid overload, interfere with daily functioning.

“It offers symptomatic relief that helps patients cope more steadily with these difficult episodes.”

It is often used when symptoms intensify and supportive relief is needed, providing additional symptomatic assistance when symptoms create noticeable physiological strain.

Quick Fact: Support for Symptoms Related to Systemic Imbalance The medication may assist with managing symptoms linked to organ-specific functional stress, which contributes to easing the overall symptom load.

Regulatory References

  1. MedlinePlus Drug Information overview

Eligibility and Restrictions for Use

Co-Epril (enalapril maleate and hydrochlorothiazide) is an authorized combination medicine used for hypertension. Official regulatory documents strictly define the patient populations who may or may not use this medicine.

Contraindicated Populations (Must Not Use)

The medicine is absolutely contraindicated (prohibited) for use in patients with the following conditions:

  • Pregnancy: Use is strictly prohibited during the second and third trimesters due to the risk of fetal injury and death. Treatment must be discontinued immediately upon detection of pregnancy.
  • Angioedema History: A history of a life-threatening swelling (angioedema) related to prior use of any ACE inhibitor, or a diagnosis of hereditary/idiopathic angioedema.
  • Concurrent Drug Use: Patients with diabetes mellitus who are concurrently taking a blood pressure medicine containing aliskiren (a direct renin inhibitor).
  • Anuria or Allergy: Patients who are unable to urinate (anuria) or who have a known hypersensitivity to sulfonamide-derived drugs (due to the hydrochlorothiazide component).
  • Recent Neprilysin Inhibitor Use: Patients who have taken a neprilysin inhibitor, such as sacubitril/valsartan, within the last 36 hours.

Use Restrictions and Limitations

  • Pediatric Use: Safety and efficacy have not been established in children. Its use is generally not recommended in this age group.
  • Renal Impairment: Use is not recommended in patients with severe renal dysfunction (creatinine clearance < 30 mL/min) and is contraindicated in anuria.
  • Lactation: Use is not recommended because both active components pass into breast milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Co-Epril, a fixed-dose combination of Enalapril (an ACE inhibitor) and Hydrochlorothiazide (a thiazide diuretic), has officially documented interactions that fall into specific regulatory categories.

Contraindicated and Restricted Combinations

The combination of Co-Epril and Sacubitril/Valsartan is formally contraindicated, requiring a mandatory 36-hour separation period between the last dose of one medication and the first dose of the other. The co-administration with Aliskiren is also contraindicated in patients with diabetes mellitus or significant renal impairment (GFR less than 60 mL/min/1.73 m²).

Pharmacodynamic and Exposure-Altering Interactions

The profile includes pharmacodynamic interactions that affect potassium balance, such as an increased risk of hyperkalaemia when Co-Epril is co-administered with potassium-sparing diuretics (e.g., spironolactone) or potassium supplements. Other antihypertensive agents and alcohol (ethanol) can cause an additive hypotensive effect.

Additionally, the regulatory documents state that Co-Epril reduces the clearance of Lithium, which can lead to increased plasma lithium concentrations. Non-steroidal Anti-inflammatory Drugs (NSAIDs) may decrease the antihypertensive effect and increase the risk of reduced renal function. The absorption of the hydrochlorothiazide component may be reduced by bile acid sequestrants like cholestyramine.

Mechanism of Action

Dual Action on Vasoactive Hormones and Fluid Balance

Co-Epril employs a dual mechanism by influencing two distinct regulatory systems involved in pressure dynamics. One component functions as an Angiotensin-Converting Enzyme (ACE) inhibitor. It binds to and blocks the active site of the ACE enzyme, thereby mediating the conversion of Angiotensin I to the vasoconstrictor Angiotensin II. This key inhibition step reduces signaling that typically causes vascular smooth muscle contraction.

The second component is a diuretic that targets ion transporters in the renal tubules. Its action decreases the reabsorption of sodium and chloride ions in the kidney, resulting in increased urinary excretion of salt and water.

This concurrent modification of both the hormonal cascade and renal function leads to two primary physiological consequences: reduced peripheral vascular resistance due to limited Angiotensin II formation and modulation of circulating fluid volume due to enhanced sodium and water excretion. These actions collectively modify the pressure dynamics exerted on artery walls.

Dosage and Administration Information

How to Use Co-Epril: Official Administration Guidelines

Co-Epril is a fixed-dose combination (FDC) tablet administered for the sustained management of blood pressure. The official guidelines define its use strictly as a maintenance therapy and not as a drug for initiating treatment. It is typically used for patients whose blood pressure is not adequately controlled with the individual components alone.


Administration Scope

Feature Official Instruction
Route of administration The medication is taken orally (by mouth).
Dosing schedule The standard regimen is one tablet once daily. Maximum daily doses are established, and the FDC is not suitable for initial therapy.
Timing in relation to meals The tablets can be taken with or without food.
Preparation requirements The tablet is to be swallowed whole. The splitting of some tablet strengths may be specifically advised against.
Age-group rules Pediatric Use: Safety and efficacy are not established in patients younger than 18 years.
Missed-dose rules If a dose is missed, skip that dose and take the next dose at the regularly scheduled time. Do not double the dose to compensate.
Special procedural conditions Use is not recommended for patients with severe renal dysfunction (Creatinine Clearance < 30 mL/min).

Instruction Classifications (High-Level)

Classification Parameter
Administration method type Oral
Frequency pattern Once daily
Use-context constraints Maintenance therapy only; Restricted use in severe renal impairment.

Resulting Procedural Structure

Official step sequence:

  • The fixed-dose tablet is administered orally.
  • The tablet is taken once daily, and the intake is flexible concerning food.
  • The fixed combination is used as ongoing treatment but not to initiate therapy.

Connection to the overall use protocol (2–4 sentences):

These official instructions establish a standardized protocol for the chronic use of Co-Epril as an oral, once-daily regimen. The key constraint is that the drug is structurally reserved for the maintenance phase of therapy, and the explicit non-recommendation for patients with severe renal impairment defines the boundaries of its authorized use.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Co-Epril


Evidence for Use in Essential Hypertension (High Blood Pressure)

Research exploring Co-Epril has focused on its use in adults diagnosed with elevated blood pressure. The research base includes Randomized Controlled Trials (RCTs). These short-term trials were designed to evaluate the combination tablet by monitoring responses compared to a placebo or to its individual components (Enalapril or Hydrochlorothiazide). Researchers primarily monitored changes in the patient's resting Systolic and Diastolic Blood Pressure (BP), which are the primary physiological outcomes measured.

The findings describe patterns observed in the studies related to measurements taken as patients approached defined blood pressure goals. The data collected from these short-term studies contribute to the broader evidence landscape for this combination. What remains uncertain, however, is the full range of outcomes from the fixed-dose combination over the long term. The majority of FDC-specific studies focus on short-term physiological responses related to blood pressure; long-term research for the reduction in major cardiovascular events is typically inferred from the existing data from the Enalapril monotherapy component.


Evidence for Use in Supporting Heart Failure Management

Research exploring the ACE inhibitor component for heart failure is derived from foundational, large-scale, long-term RCTs that studied the Enalapril component alone. These studies monitored outcomes such as hospitalization rates and mortality. Studies monitored changes measured during the study period, providing insight into the long-term patterns observed in the studies.

A key point of research uncertainty is that the extensive long-term data for morbidity and mortality that contributes to the evidence base used the Enalapril monotherapy component. Studies directly assessing the long-term impact of this specific fixed-dose combination on these vital survival outcomes in heart failure are not as widely documented, meaning the evidence is limited concerning the FDC itself for these specific long-term outcomes.


Long-Term Studies and Durability of Response

Research has explored the durability of the observed responses, primarily through the long-term follow-up of the large-scale trials originally conducted for the individual components. This extended data provides context for outcomes reflecting daily functioning and overall cardiovascular health. Comparative evidence is lacking to definitively contextualize the long-term durability of the FDC versus the separate components.


Evidence in Specific Patient Populations

Research describes the specific populations that were included in the clinical evaluations, such as adults and older adults. Data for certain groups remain insufficient when examining the medication in patients with complex comorbid conditions. Research focusing on the use of this fixed-dose combination in populations such as children or pregnant individuals is not the primary focus of the existing evidence record. Therefore, results apply only to the populations studied in the research that regulators rely on.

Frequently Asked Questions (FAQ)

Common questions about Co-Epril (FAQ)

Q: How quickly should Co-Epril start lowering my blood pressure after the first dose?

The onset of action for Co-Epril is relatively quick due to its dual components. Official documents indicate that the diuretic portion typically begins working within two hours of a dose, reaching its maximum effect around four hours. Similarly, the primary blood-pressure-lowering effect from the ACE inhibitor component also begins within a few hours.

Q: How long will it take to see the full effect of Co-Epril on my blood pressure?

While the medication begins working on the first day, achieving the full and optimal blood pressure reduction may require a longer period. Official product information indicates that the full therapeutic effect, particularly from the ACE inhibitor component, may take several weeks to be fully realized.

Q: Is it true that blood pressure medication like Co-Epril can cause sexual problems?

Regulatory documents list a decrease in sexual ability as a possible side effect of this combination medicine. It is described as a less common symptom that has been reported by patients.

Q: Can Co-Epril affect my blood sugar levels?

Official information indicates that the diuretic component in Co-Epril (Hydrochlorothiazide) has been associated with changes in blood sugar control. Due to this potential effect, it is noted as a concern that requires clinical observation, particularly for patients with diabetes.

Q: Does Co-Epril increase sensitivity to the sun or cause rash?

Regulatory documents indicate that rash is a reported adverse reaction. Additionally, photosensitivity, or increased sensitivity to the sun, has also been reported by patients using this combination, often linked to the diuretic component.

Q: Are there any mental side effects or mood changes linked to Co-Epril?

Official product information describes certain central nervous system effects. Less common symptoms that have been reported include feelings of drowsiness and irritability.

Q: How is Co-Epril different from other common blood pressure medicines?

Co-Epril is defined as a Fixed-Dose Combination (FDC) medicine, meaning it simultaneously uses two distinct agents to influence blood pressure. Its unique action is to reduce the tension in blood vessels via an ACE inhibitor while also reducing the body's circulating fluid volume via a diuretic. This dual action is intended to leverage two different pathways to address blood pressure.

Q: Can Co-Epril be used to treat health conditions other than high blood pressure?

While the specific fixed-dose combination (FDC) of Co-Epril is primarily indicated for the treatment of hypertension, the ACE inhibitor component (Enalapril) is authorized for use in other conditions. Official labeling for the monotherapy component includes indications for managing heart failure and for asymptomatic left ventricular dysfunction.

Q: Can Co-Epril affect kidney function in the long term?

Official documents note that serious effects on the renal system, including acute renal failure, have been reported. Due to these risks, the medicine is not recommended for patients with severe pre-existing renal impairment. For patients with milder impairment, regulatory documents state that monitoring of kidney function and potassium levels is a required safety measure.

Q: Is Co-Epril a medication that needs to be taken for the rest of my life?

Co-Epril is indicated for the sustained management of high blood pressure (hypertension). As hypertension is typically a chronic condition, official use protocols are based on the need for sustained, long-term therapy to maintain blood pressure goals.

Q: Will Co-Epril still work if I miss taking a dose occasionally?

The official regulatory guidance for a missed dose is to skip it entirely and then take the next dose at the regularly scheduled time. Doubling the dose to compensate is explicitly advised against in regulatory instructions.

Q: Does Co-Epril interact with common supplements or herbal products?

Regulatory documents list explicit warnings for specific types of supplements. Interactions are noted for products that affect potassium levels, such as potassium supplements, which can increase the risk of high potassium. Additionally, certain agents like bile acid sequestrants may reduce the absorption of the diuretic component.

Q: Are there certain foods or drinks I should avoid while taking Co-Epril?

Official safety information includes warnings regarding alcohol consumption, stating it can cause an additive blood pressure lowering effect. The official interaction profile also includes substances that can raise potassium levels, which means careful consideration is warranted when consuming high intakes of potassium-rich foods.

Q: Can Co-Epril be used by people with a known history of heart failure?

Official documents state that use of this combination medicine in patients with severe congestive heart failure requires caution. This is because the medication may lead to kidney problems in this specific patient population, and clinical monitoring is required.

Q: Is Co-Epril appropriate for use in older adults?

Regulatory labeling confirms that older adults were included in the clinical studies used to evaluate Co-Epril. The drug is used in this population, but the labeling indicates that careful consideration is generally applied, particularly with attention paid to renal function and the body's volume status.

Q: What does the research evidence actually show about the long-term benefits of Co-Epril?

Research specific to the combination tablet has focused on monitoring blood pressure reductions in short-term studies. For long-term outcomes, the evidence is largely inferred from the primary component (Enalapril), which official documents indicate has been shown to maintain its antihypertensive effects during sustained therapy.

Q: Why do some people need two or more medications to control blood pressure?

Co-Epril is a combination of two medications and is specifically authorized for patients whose high blood pressure is not adequately controlled by taking a single agent alone. This highlights that for many patients, official treatment protocols recognize that a single medication is insufficient to reach blood pressure goals.

Q: Why is it important to keep track of my blood pressure when starting Co-Epril?

Clinical monitoring of blood pressure is essential when initiating this medication to achieve an optimal reduction. Furthermore, official safety information indicates that hypotension, or low blood pressure, is a common side effect that requires observation.

Q: Does Co-Epril have a high risk of drug-drug interactions?

The official regulatory labeling for Co-Epril lists an extensive profile of drug-drug interactions, which fall into multiple categories. These include outright contraindications (meaning they must not be used together) with certain drugs, as well as several agents that require careful clinical monitoring if used concurrently.

Q: Will Co-Epril help prevent a stroke or heart attack?

Treating hypertension is fundamentally intended to reduce the long-term risk of major cardiovascular events, such as stroke and heart attack. While the direct fixed-combination research focuses on blood pressure, the evidence for this protective benefit is largely inferred from the long-term studies of the ACE inhibitor component.

How should Co-Epril be stored and disposed of?

How to Store and Dispose of Co-Epril?

Co-Epril (Enalapril maleate/Hydrochlorothiazide) tablets must be stored according to official regulatory requirements to maintain product stability and safety.

Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature (20 C to 25 C), protected from excess heat.
Protection Must be protected from moisture; do not store in the bathroom.
Container Keep in the original container, which must be kept tightly closed.
Child Safety Store out of the sight and reach of children.

Disposal Instructions

Unused or expired Co-Epril must be properly discarded. Do not flush the tablets down a toilet or dispose of them in wastewater. The preferred method is to utilize a drug take-back program where available. Otherwise, mix the tablets with an undesirable substance, place the mixture in a sealed container, and discard it in the household trash according to local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Co-Epril found in:

A-Z Index: